VDI Guideline 5708 “Bioprinting, methods and definitions”: What sounds technical and sober at first glance is an important step forward in the future field of 3D bioprinting. The guideline was developed under Dr. Hanna Hartmann from the NMI in Reutlingen and Prof. Dr. Jürgen Groll from the University Hospital of Würzburg. It creates a binding, practical basis for reproducible and quality-assured bioprinting procedures.

3D bioprinting is a great hope in the field of regenerative medicine to produce miniaturized tissues and organ precursors with biological functionality. Today, however, scientists are still working on the challenge of producing a printable and at the same time compatible starting material.

Zebrafish can completely replace damaged heart muscle cells: The affected organ becomes fully functional again. Researchers at Ulm University have discovered that a specific cell-to-cell communication signal helps them to cope better with replication stress. This stress inhibits tissue regeneration in humans and mammals as they age. In Zebrafish a signalling protein ensures that the cells of the damaged organ continue to divide and thus multiply.

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

With mice, researchers showed that experimentally induced lack of blood flow in the brain epigenetically reprograms astrocytes into brain stem cells, which in turn can give rise to nerve progenitor cells. This discovery shows that astrocytes could potentially be used in regenerative medicine to replace damaged nerve cells.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.

Project SMARTGAIT - 13/09/2023

Safe and cost-effective analysis of neurological gait disorders with AI

Stroke, Parkinson's disease and multiple sclerosis often resulting in gait disorders in those affected. Gait analyses play a crucial role in the successful evaluation and therapy of such disorders. Current measurement methods are costly and time-consuming. The SMARTGAIT project is therefore developing an innovative AI-based system aimed at performing meaningful gait analyses with the help of simple smartphone video recordings.

Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).

Elastin as artificial muscle material - 02/03/2022

Artificial muscle from proteins for diverse future applications

As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.

Organ failure due to fatty liver - 24/09/2020

HepaRegeniX develops an active substance for liver regeneration

When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

Dossier - 09/03/2015

Advances in the study and treatment of liver diseases

Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively.

Dossier - 10/11/2014

Cell and gene therapies from bench to bedside

While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.

Dossier - 20/12/2012

Medical technology serving healthcare

Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.

Dossier - 12/03/2012

Regenerative medicine makes use of patients own resources

Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.